Neurosurgical patients are at great risk for venous thromboembolism. Thromboprophylaxis is either with unfractionated heparin or low molecular weight heparin (LMWH). In neurosurgery, this is a matter of debate because of fear from bleeding. Few randomized studies show that chemical prophylaxis is safe after elective neurosurgeries. Prophylaxis with gradual elastic stocking and venous pump may b...

A 35-year-old woman with recurrent severe placenta-mediated pregnancy complications in her 2 pregnancies asks: Will low-molecular-weight heparin help prevent recurrent placenta-mediated pregnancy complications in my next pregnancy? We performed a meta-analysis of randomized controlled trials (RCTs) comparing low-molecular-weight heparin (LMWH) vs no LMWH for the prevention of recurrent placenta...

PURPOSE To evaluate safety and efficacy of low molecular weight heparin given for various indications during pregnancy. METHODOLOGY A detailed retrospective analysis of all the patients who received low molecular weight heparin (LMWH) for various indications over a period of 3 years (2010-2012) at a tertiary care hospital in Northern India was performed. RESULTS Fifty-five patients received...

BACKGROUND The use of low-molecular weight heparin (LMWH) during percutaneous coronary intervention (PCI) has been limited by the presumed inability to monitor its anticoagulant effect using bedside assays. OBJECTIVES This study was designed to compare the dose-response of enoxaparin, dalteparin and unfractionated heparin (UFH) on the activated clotting time (ACT), and to determine whether th...

Neonatal thromboembolism occurs with various predisposition and triggers. Early diagnosis of the thrombosis is challenging essential for therapeutic interventions. We herein report one newborn who presented transient patient arterial underwent Doppler received low molecular weight heparin (LMWH) subcutaneously. Newborns suspected having may need urgent surgical intervention along thrombolytic a...

Abbreviations: ACD 5 absolute claudication distance; CI 5 confidence interval; INR 5 international normalized ratio; LMWH 5 low-molecular-weight heparin; MI 5 myocardial infarction; NASCET 5 North American Symptomatic Carotid Endarterectomy Trial; PGE1 5 prostaglandin E1; PGI2 5 prostaglandin I2; PTFE 5 polytetrafluoroethylene; rtPA 5 recombinant tissue plasminogen activator; tPA 5 tissue plasm...

BACKGROUND AND OBJECTIVE Either low molecular weight heparin (LMWH) or unfractionated heparin (UH) may be used for the prophylaxis of post-operative venous thromboembolic disease (VTD) in elective hip replacement. This study was aimed at assessing the cost-effectiveness of LMWH over UH from the society perspective, which considers all the outcomes occurring in the life-long time horizon. DESI...

Immediate anticoagulant treatment is essential to reduce morbidity and mortality in patients with acute venous thromboembolism (VTE). Currently, rapid anticoagulation can only be achieved with parenteral anticoagulants, such as heparin or low-molecular-weight heparin (LMWH). Weight-adjusted LMWH is the treatment of choice, because it produces predictable anticoagulation and does not require coa...

Patients with acute deep vein thrombosis (DVT) were treated with a body-weight independent dosage of 2 x 8000 aXa IU low-molecular-weight heparin (LMWH) Certoparin. After the subcutaneous administration of 8000 IU Certoparin, pharmacodynamic parameters did not differ between patients and healthy volunteers, and the AUC of the anticoagulant effects were not related to body weight. Two clinical t...

Adequate initial anticoagulant therapy of deep venous thrombosis (DVT) is required to prevent thrombus growth and pulmonary embolism (PE). Intravenous unfractionated heparin (UFH) is being replaced by low-molecular-weight heparin (LMWH) as the anticoagulant of choice for initial treatment of venous thromboembolism (VTE). Both agents are relatively safe and effective when used to treat VTE, with...